Clinical trials directed to investigate the anti-cancer effect of specific NLRP3 inflammasome inhibitors which either target components of its canonical signaling pathway or are specific to the NLRP3 protein, have not been performed so far (49). This evidence concerns the gene NLRP3 and cancer.